# Study to Evaluate HT-6184 in Healthy Subjects

> **NCT05447546** · PHASE1 · COMPLETED · sponsor: **Halia Therapeutics, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Normal Healthy Subjects

## Interventions

- **DRUG:** HT-6184
- **DRUG:** HT-6184 Placebo

## Key facts

- **NCT ID:** NCT05447546
- **Lead sponsor:** Halia Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-15
- **Primary completion:** 2023-07-20
- **Final completion:** 2023-07-20
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05447546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05447546, "Study to Evaluate HT-6184 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05447546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*